Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,759
  • Shares Outstanding, K 3,736
  • Annual Sales, $ 11,690 K
  • Annual Income, $ -38,490 K
  • EBIT $ -33 M
  • EBITDA $ -30 M
  • 60-Month Beta 0.03
  • Price/Sales 0.06
  • Price/Cash Flow N/A
  • Price/Book 0.97
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -33.24
  • Most Recent Earnings $-6.28 on 11/14/25
  • Next Earnings Date 03/30/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4620 +22.27%
on 03/11/26
0.9940 -43.17%
on 03/02/26
-0.0421 (-6.94%)
since 02/11/26
3-Month
0.4620 +22.27%
on 03/11/26
1.8700 -69.79%
on 01/16/26
-0.8751 (-60.77%)
since 12/11/25
52-Week
0.4620 +22.27%
on 03/11/26
15.4800 -96.35%
on 04/25/25
-11.3476 (-95.26%)
since 03/11/25

Most Recent Stories

More News
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March...

JAGX : 0.5649 (+19.99%)
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Strengthening balance sheet and capitalization is a key Jaguar priority

JAGX : 0.5649 (+19.99%)
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized...

JAGX : 0.5649 (+19.99%)
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt

JAGX : 0.5649 (+19.99%)
Jaguar Health Announces a Special One-time Stock Dividend

Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt

JAGX : 0.5649 (+19.99%)
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an additional...

JAGX : 0.5649 (+19.99%)
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday,...

JAGX : 0.5649 (+19.99%)
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions)

JAGX : 0.5649 (+19.99%)
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure

JAGX : 0.5649 (+19.99%)
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center...

JAGX : 0.5649 (+19.99%)

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing...

See More

Key Turning Points

3rd Resistance Point 0.7686
2nd Resistance Point 0.6867
1st Resistance Point 0.6258
Last Price 0.5649
1st Support Level 0.4830
2nd Support Level 0.4011
3rd Support Level 0.3402

See More

52-Week High 15.4800
Fibonacci 61.8% 9.7431
Fibonacci 50% 7.9710
Fibonacci 38.2% 6.1989
Last Price 0.5649
52-Week Low 0.4620

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar